Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: A quantitative structure activity relationships (QSARs) analysis

Current Medicinal Chemistry

Volumn 17, Issue 28, 2010, Pages 3162-3214

  Kontogiorgis, C ^a   Hadjipavlou Litina, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Lipophilicity; QSAR; Steric factors; Thormboxane receptor antagonists; Thromobxane synthase inhibitors

Indexed keywords

1 [(SULFONYL)AMINO]ALKYLINDOLE DERIVATIVE; 3 [2 [[(4 CHLOROPHENYL)SULFONYL]AMINO]ETHYL]BENZENEPROPANOIC ACID DERIVATIVE; 3 ETHYL 7 ISOPROPYL 1 AZULENESULFONIC ACID SODIUM SALT; 3,4 DIHYDRIQUINOLIN 2(1H) ONE DERIVATIVE; 5 [PHENYL(3 PYRIDYL)METHYL ENEAMINOOXY]PENTANOIC ACID DERIVATIVE; 8 [[(4 CHLOROPHENYL)SULFONYL]AMINO] 4 [3 (3 PYRIDINYL)PROPYL]OCTANOIC ACID DERIVATIVE; [(1 H IMIDAZOL 1 YL)METHYL]PYRROLE DERIVATIVE; [(3PYRIDINYL)METHYL]PYRROLE DERIVATIVE; [4[1 (BENZENESULFONAMIDO)ALKYL]PHENYL]ALKANOIC ACID DERIVATIVE; [[(2 (1H) IMIDAZOL 1 YL)ETHYLIDENE]AMINO]OXY]ALKANOIC ACID DERIVATIVE; AZULENE DERIVATIVE; BENZOFURAN DERIVATIVE; DAZMEGREL; KT 2962; KTI 32; OMEGA PHENYL OMEGA(3 PYRIDYL)ALKENOIC ACID DERIVATIVE; OMEGA PYRIDYLALKENOIC ACID DERIVATIVE; TETRALIN DERIVATIVE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ARACHIDONIC ACID; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE;

ANIMAL TISSUE; DRUG ACTIVITY; DRUG DESIGN; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REVIEW; SUBSTITUTION REACTION; SWINE; TREATMENT RESPONSE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

ARACHIDONIC ACID; AZULENES; DRUG DESIGN; ENZYME INHIBITORS; IMIDAZOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE-A SYNTHASE;

EID: 79952199147     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986710792231978     Document Type: Review

References (105)

1. Majerus, M.; Broza, G. J.; Miletich, J. P.; Tollesfsen, D. M. In: The Goodman and Gilman's Pharmacological Basis of Therapeutics; Goodman, L. S.; Gilman, A. G.; Hardmann, L. G.; Limbird, L. E.; Eds.; McGraw-Hill: New York, 1996, pp. 1341-1359.
2. Fitzgerald, D.; Roy, L.; Catella, F.; Fitzgerald, G. A. Platelet activation in unstable coronary disease. N. Engl. J. Med., 1986, 315, 983-989. (Pubitemid 16028578)
3. Eikelboom, J. W.; Hirsh, J.; Weitz, J. I.; Johnston, M.; Yi, Q.; Yusuf, S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002, 105, 1650-1655. (Pubitemid 34298607)
4. Hamm, C. W.; Lorenz, R. L.; Bleifeld, W.; Kupper, W.; Wober, W.; Weber, P. C. Biochemical evidence of platelet activation in patients with persistent unstable angina. J. Am. Coll. Cardiol., 1987, 10, 998-1006.
5. Granger, J. P.; Alexander, B. I.; Benett, W. A.; Khalil R. A. Am. J. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension, 2001, 38, 718-722.
6. Friedman, S. A. Preeclampsia: a review of the role of prostaglandins. J. Obstet. Gynecol., 1988, 71, 122-137. (Pubitemid 18025090)
7. Walsh, S. W. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J. Obstet. Gynecol., 1985, 152, 335-340. (Pubitemid 15049763)
8. 2 by coronary arteries after thrombolysis. Am. Heart J., 1993, 125, 277-284. (Pubitemid 23055254)
9. Saldeen, P.; Nilsson, I. M.; Saldeen, T. Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. Thromb. Res., 1983, 32, 461-467. (Pubitemid 14243217)
10. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ. Res., 1989, 65, 83-94. (Pubitemid 19173135)
11. 2 receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. Am. J. Resp. Crit. Care Med., 2002, 166, 208-214. (Pubitemid 34765458)
12. Dogne, J. M.; de Leval, X.; Benoit, P.; Rolin, S.; Pirotte, B.; Masereel, B. Therapeutic potential of thromboxane inhibitors in asthma. Expert Opin. Investig. Drugs, 2002, 12, 275-281. (Pubitemid 34144870)
13. 2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. Shock, 2000, 13, 307-313.
14. 2 biosynthesis in atherosclerosis, Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 4511-4515.
15. Pratico, D.; Cyrus, T.; Li, H.; FitzGerald, G. A. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood, 2000, 96, 3823-3826.
16. FitzGerald, G. A.; Austin, S.; Egan, K.; Cheng, Y.; Pratico, D. Cyclo-oxygenase products and atherothrombosis. Ann. Med., 2000, 32(Suppl 1), 21-26. (Pubitemid 32115803)
17. 2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis. J. Rheumatol., 2002, 29, 2106-2113
18. 2 production in patients with systemic lupus erythematosus. J. Clin. Invest., 1985, 76, 1011-1018. (Pubitemid 16225597)
19. Reilly, I. A.; Roy, L.; Fitzgerald, G. A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br. Med. J., 1986, 292, 1037-1039. (Pubitemid 16137039)
20. Haurand, M.; Ullirich, V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J. Biol. Chem., 1985, 260, 15059-15067. (Pubitemid 16147992)
21. Ruan, K. H.; Wang, L. H.; Wu, K. K.; Kulmacz, R. J. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum. J. Biol. Chem., 1993, 268, 19483-19490. (Pubitemid 23270730)
22. 2 levels in patients with classic and variant angina Pectoris. Circulation., 1981, 64, 1107-1115. (Pubitemid 12236136)
23. Jakubowski, J. A.; Smith, G. F.; Sall, D. J. Future Antitrombotic Therapy. In, Bristol JA, Ed. Annu. Rep. Med. Chem., 1992, 27, 99-108.
24. 2 receptor antagonists. Med. Res. Rev., 1991, 11, 503-579.
25. 2 (TP) Receptor Antagonists. Bioorg. Med. Chem. Lett., 1996, 6, 349-352. (Pubitemid 26081800)
26. Collinghton, E. W.; Finch, H. Thromboxane Synthase Inhibitors and Receptor Antagonists, In: Bristol JA, Ed. Annu. Rep. Med. Chem., 1989, 25, 99-108.
27. Fiddler, G. I.; Lumley, P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation, 1990, 81, 169-178.
28. Vezza, R.; Habib, A.; FitzGerald, G. A. Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J. Biol. Chem., 1999, 274, 12774-12779.
29. 2 receptor, cDNA cloning, expression and northern blot analysis. Biochem. Biophys. Res. Commun., 1992, 184, 1197-1203.
30. 2 receptors. J. Biol. Chem., 1998, 273, 475-483. (Pubitemid 28042235)
31. 2 receptor, high affinity for the agonist ligand I-BOP. Prostaglandins, 1996, 52, 203-216.
32. 2 receptor gene in human uterus. Biol. Reprod., 1992, 47, 105-117.
33. 2 receptor gene. Biochem. Biophys. Res. Commun., 1999, 256, 391-397. (Pubitemid 29298896)
34. Dogne, J. M.; de Leval, X.; Delarge, J.; David, J. L.; Maserell, B. New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem., 2000, 7, 609-628. (Pubitemid 30396420)
35. Coleman, R. A.; Smith, W. I.; Naruyima, S. International Union of Pharmacology classification of prostanoid receptors, properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 1994, 46, 205-229. (Pubitemid 24185151)
36. 2 receptor. Nature, 1991, 349, 617-620. (Pubitemid 21912117)
37. Tsuboi, K.; Sugimoto, Y.; Ichikawa, A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat., 2002, 68, 535-556. (Pubitemid 35247419)
38. 2 receptors in platelets and blood vessels, evidence for different receptors. J. Pharmacol. Exp. Ther., 1985, 233, 418-424. (Pubitemid 15122041)
39. 2 analogs in platelets and blood vessels. Eur. J. Pharmacol., 1988, 148, 309-315.
40. Morinelli, I. A.; Niewiarowski, S.; Daniel, J. L.; Smith, J. B. Luminal disequilibrium pH and ammonia transport in outer medullary collecting duct. Am. J. Physiol., 1987, 253, 1035-1057.
41. 2 receptor subtypes. A radioligand binding study of human platelets. J. Clin. Invest., 1989, 84, 1883-1891.
42. 2 receptors. Am. J. Physiol., 1991, 260, 327-334.
43. 2 receptor antagonists. Bioorg. Med. Chem., 2002, 10, 1399-1415. (Pubitemid 34214704)
44. 2 receptor by seratrodast, a structural approach. Bioorg. Med. Chem. Lett., 1999, 9, 2867-2870. (Pubitemid 29481179)
45. Serruys, P. W.; Rutch, W.; Heyndrickx, G. R.; Dachin, N.; Mast, E. G.; Wijns, W.; Rensing, B. J.; Vos, J.; Stibbe, J. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, doubleblind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation, 1991, 84, 1568-1580.
46. Chamorro, A. TP receptor antagonism, a new concept in atherothrombosis and stroke prevention. Cerebrovasc. Dis., 2009, 27(Suppl 3), 20-27.
47. Dogne, J.-M.; de Leval, X.; Hanson, J.; Frederich, M.; Lambermont, B.; Ghuyssen, A.; Casini, A.; Masereel, B.; Ruan, K.-H.; Pirotte, B.; Kolh, P. New developments on thromboxane and prostacyclin modulators part I, thromboxane modulators. Curr. Med. Chem., 2004, 11, 1223-1241. (Pubitemid 38585063)
48. Dogne, J.-M.; Hanson, J.; de Leval, X.; Masereel, B.; Kolh, P.; Pirotte, B. New developments on thromboxane modulators. Mini-Rev. Med. Chem., 2004, 4, 649-657. (Pubitemid 38961230)
49. Dogne, J.-M.; Hanson, J.; de Leval, X.; Pratico, D.; Pace-Asciak, C. R.; Drion, P.; Pirotte, B.; Ruan, K.-H. From the design to the clinical application of thromboxane modulators. Curr. Pharm. Des., 2006, 11, 903-923.
50. 2 receptor antagonists. 4-[2-(4-substituted phenylsulfonylamino) ethylthio]phenoxyacetic acids and related compounds. Chem. Pharm. Bull., 1995, 43, 1132-1136.
51. Hadjipavlou-Litina, D.; Kontogirogis, C. A. Quantitative structure activity relationships on thromboxane inhibitors internet electr. J. Mol. Des., 2002, 1, 134-141.
52. Kumar, R.; Singh, P. Quantitative structure-activity relationship study of iodinated analogues of trimetoquinol as highly potent beta 2-adrenoceptor ligands. Indian J. Biochem. Biophys., 1998, 35, 390-392. (Pubitemid 128376854)
53. 2 receptor antagonists. J. Chem. Inf. Comput. Sci., 1998, 38, 925-938. (Pubitemid 128611010)
54. Doble, M.; Karthikeyan, S.; Padmawar, P. A.; Akamanchi, K. G. SAR studies of paeonol analogues for inhibition of platelet aggregation. Bioorg. Med. Chem., 2005, 13, 5996-6001. (Pubitemid 41399909)
55. Nicolotti, O.; Gillet, V. J.; Fleming, P. J.; Green, D. V. Multiobjective optimization in quantitative structure-activity relationships: deriving accurate and interpretable QSARs. J. Med. Chem., 2002, 45, 5069-5080. (Pubitemid 35278703)
56. Nicolotti, O.; Giangreco, I.; Miscioscia, T. F.; Carotti, A. Improving quantitative structure-activity relationships through multiobjective optimization. J. Chem. Inf. Model., 2009, 49, 2290-2302.
57. Nicolotti, O.; Carotti, A. QSAR and QSPR studies of a highly structured physicochemical domain. J. Chem. Inf. Model., 2006, 46, 264-276. (Pubitemid 43282121)
58. Nicolotti, O.; Miscioscia, T. F.; Carotti, A.; Leonetti, F.; Carotti, A. An integrated approach to ligand-and structure-based drug design: development and application to a series of serine protease inhibitors. J. Chem. Inf. Model., 2008, 48, 1211-1226.
59. Du, Q. S.; Huang, R. B.; Chou, K. C. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci., 2008, 9, 248-260
60. Iizuka, K.; Akahane, A.; Momose, D.; Nakazawa, M.; Tanouchi, T.; Kawamura, M.; Ohyama, I.; Kajiwara, I.; Iguchi, Y.; Okada, T.; Taniguchi, K.; Miyamoto, T.; Hayashi, M. Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives. J. Med. Chem., 1981, 24, 1139-1148 (Pubitemid 12208769)
61. Kato, K.; Ohkawa, S.; Terao, S.; Terashita, Z.; Nishikawa, K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J. Med. Chem., 1985, 28, 287-294 (Pubitemid 15137931)
62. Martinez, G. R.; Walker, K. A. M.; Hirschfeld, D. R.; Maloney, P. J.; Yang, D. S.; Rosenkranz, R. P. [(1H-imidazol-1-yl) methyl]-and [(3-pyridinyl) methyl]pyrroles as thromboxane synthetase inhibitors. J. Med. Chem., 1989, 32, 890-897. (Pubitemid 19100207)
63. 2 synthase and cAMP phosphodiesterase. J. Med. Chem., 1992, 35, 620-628.
64. Archibald, J. L.; Bradley, G.; Opalko, A.; Ward, T. J.; White, J. C.; Ennis, C.; Shepperson, N. B. Design of an antithromboticantihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines. J. Med. Chem., 1990, 33, 646-652. (Pubitemid 20047586)
65. Fujita, M.; Seki, T.; Inada, H.; Shimizu, K.; Takahama, A.; Sano, T. Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). Bioorg. Med. Chem. Lett., 2002, 12, 771-774. (Pubitemid 34164615)
66. Fujita, M.; Seki, T.; Inada, H.; Shimizu, K.; Takahama, A.; Sano, T. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs. Bioorg. Med. Chem. Lett., 2002, 12, 341-344. (Pubitemid 34113898)
67. Takeuchi, K.; Happ, A. M.; Mais, D. E.; Layman, N.; Utterback, B. G.; Wyss, V. L.; Jakubowski, J. A. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition-I. Synthesis, structure-activity relationship, and evaluation of substituted omega-phenyl-omega-(3-pyridyl) alkenoic acids. Bioorg. Med. Chem., 1994, 2, 743-755.
68. Dickinson, R. P.; Dack, K. N.; Steele, J.; Tute, M. S. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl-and 3-pyridinylalkylsubstituted 3-[2-[(arylsulfonyl) amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. Bioorg. Med. Chem. Lett., 1996, 6, 1691-1695.
69. Takeuchi, K.; Kohn, T. J.; True, T. A.; Mais, D. E.; Wikel, J. H.; Utterback, B. G.; Wyss, V. L.; Jakubowski, J. A. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl) alkenoic acid derivatives and related compounds. J. Med. Chem., 1998, 41, 5362-5374. (Pubitemid 29031320)
70. 2 receptor antagonists and synthase inhibitors. J. Med. Chem., 1999, 42, 1235-1249. (Pubitemid 29181146)
71. Bhagwat, S. S.; Gude, C.; Boswell.; Contrardo, N.; Cohen, D. S.; Dotson, R.; Mathis, J.; Lee.; W.; Furness, P.; Zoganas, H. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl) sulfonyl]amino]-4-(3-(3-pyridinyl) propyl) octanoic acid and analogs. J. Med. Chem., 1992, 35, 4373-4383
72. Cozzi, P.; Giordani, A.; Menichincheri, K.; Pillan, A.; Pinciroli, V.; Rossi, A.; Tonani, R.; Volpi, D.; Tamburin, M.; Ferrario, R.; Fusar, D.; Salvati, P. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition, [[[2-(1H-imidazol-1-yl) ethylidene]amino]oxy]alkanoic acids. J. Med. Chem., 1994, 37, 3588-3604. (Pubitemid 24334614)
73. Bock, M. G.; DiPardo, R. M.; Williams, P. D.; Pettibone, D. J.; Clineschmidt, B. V.; Ball, R. G.; Veber, D. F.; Freidinger, R. M. Azulene Derivatives: New non-prostanoid thromboxane A, Receptor Antagonists. J. Med. Chem., 1990, 33, 2323.
74. 2 receptor antagonist KT2-962, modifications of this moiety and the resulting activities. Bioorg. Med. Chem. Lett., 1993, 3, 1687-1692. (Pubitemid 23270212)
75. Yokota, M.; Uchibori, S.; Hayashi, H.; Koyama, R.; Kosakai, K.; Wakabayashi, S.; Tomiyama, T. Azulene derivatives as TXA2/PGH2 receptor antagonists-II. Synthesis and biological activity of 6-mono-and 6-dihydroxylated-isopropylazulenes. Bioorg. Med. Chem. 1996, 4, 575-591. (Pubitemid 26164631)
76. 2 receptor antagonists. J. Med. Chem., 1993, 36, 791-800. (Pubitemid 23118770)
77. Dickinson, R. P.; Dack, K. N.; Steele, J.; Tute, M. S. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl-and 3-pyridinylalkylsubstituted 3-[2-[(arylsulfonyl) amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. Bioorg. Med. Chem. Lett., 1996, 6, 1691-1695.
78. Dack, K. N.; Dickinson, R. P.; Long, C. J.; Steele, J. Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[[(4-chlorophenyl) sulfonyl]-amino]ethyl) benzenepropanoic acid derivatives as potent thromboxane receptor antagonists. Bioorg. Med. Chem. Lett., 1998, 8, 2061-2066. (Pubitemid 28561579)
79. Dickinson, R. P.; Dack, K. N.; Steele, J. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl-and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl) amino]ethyl] benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists. J. Med. Chem., 1997, 40, 3442-3452.
80. Cimetière, Dubuffet, T.; Muller, O.; Descombes, J.-J.; Simonet, S.; Laubie, M.; Verbeuren, T. J.; Lavielle, G. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg. Med. Chem. Lett., 1998, 8, 1375-1380. (Pubitemid 28261305)
81. 2 and leukotriene D4 of [4-[1- (benzenesulfonamido) alkyl]phenyl]alkanoic acid derivatives. Chem. Pharm. Bull., 1997, 45, 849-862. (Pubitemid 27255099)
82. Ohno, M.; Miyamoto, M.; Hoshi, K.; Takeda, T.; Yamada, T.; Ohtake, A. Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist, synthesis, structure-activity relationship, and evaluation of benzofuran derivatives. J. Med. Chem., 2005, 48, 5279-5294. (Pubitemid 41113914)
83. Ohno, M.; Tanaka, Y.; Miyamoto, M.; Takeda, T.; Hoshi, K.; Yamada, N.; Ohtake, A. Development of 3, 4-dihydro-2H-benzo [1, 4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists. Bioorg. Med. Chem., 2006, 14, 2005-2021. (Pubitemid 43199531)
84. Hansch, C.; Zhang, L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab. Rev., 1993, 25(1-2), 1-48. (Pubitemid 23084972)
85. oct from structures. Chem. Rev., 1993, 93, 1281-1306.
86. Hansch, C.; Leo, A. J.; Taft, W. R. A survey of survey of Hammett substituent constants and resonance and field parameters. Chem. Rev., 1991, 91, 165-169.
87. Unger, S. H.; Hansch, C. Quantitative models of steric effects. Prog. Phys. Org. Chem., 1976, 12, 91.
88. Hansch, C.; Leo, A. J. Exploring QSAR, Fundamentals and Applications in Chemistry and Biology, American Chemical Society, Washington, DC, 1995.
89. Hansch, C.; Leo, A. J.; Hoekman, D. Exploring QSAR, Hydrophobic, Electronic and Steric Constants, American Chemical Society, Washington, DC, 1995.
90. Silippo, C.; Vittoria, A. In: Comprehensive Medicinal Chemistry Three-Dimensional Structure of Drugs, Hansch, C.; Sammes, P. G.; Taylor, J. B.; Eds, Pergamon Press, New York, 1990, Vol 4, Chp. 18, 4, p. 153.
91. Verloop, A. The Sterimol Approach to Drug Design, Dekker, New York, 1987.
92. C-QSAR, version 4 31, Biobyte Corp, Claremont, CA, 2003, available from: www.biobyte.com
93. Cramer, R. D. III, Bruce, J. D.; Patterson, D. E.; Frank, I. E. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat., 1988, 7, 18.
94. Golbraikh, A.; Shen, M.; Xiao, Z.; Xiao, Y. D.; Lee, K. H.; Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. J. Comput. Aided Mol. Des., 2003, 17(2-4), 241-253. (Pubitemid 37062785)
95. Pogliani, L. Modeling with special descriptors derived from a medium-sized set of connectivity indices. J. Phys. Chem., 1996, 100, 18065-77. (Pubitemid 126788760)
96. Agrawal, V. K.; Singh, J.; Khadikar, P. V.; Supuran, C. T. QSAR study on topically acting sulfonamides incorporating GABA moieties, a molecular connectivity approach. Bioorg. Med. Chem. Lett., 2006, 16, 2044-2051. (Pubitemid 43267406)
97. Johnson, S. R. The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy). J. Chem. Inf. Model., 2008, 48, 1, 25-26.
98. Egan, W. J.; Morgan, S. L. Outlier Detection in Multivariate Analytical Chemical Data. Anal. Chem., 1998, 70, 2372-2379.
99. Yoshimoto, T.; Yamamoto, S.; Okuma, M.; Hayaishi, O. Solubilization and resolution of thromboxane synthesizing system from microsomes of bovine blood platelets. J. Biol. Chem., 1977, 252, 5871-5874. (Pubitemid 8180221)
100. Needleman, P.; Raz, A.; Ferrendelli, J. A.; minkes, M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc. Natl. Acad. Sci. U. S. A., 1977, 74, 1716-1720. (Pubitemid 8087047)
101. Cross, P. E.; Dickinson, R. P.; Parry, M. J.; Randall, M. J. Selective thromboxane synthetase inhibitors. 4. 2-(1H-imidazol-1-ylmethyl) carboxylic acids of benzo [b]furan, benzo [b]thiophene, indole, and naphthalene. J. Med. Chem., 1986, 29, 1643-1650. (Pubitemid 16018188)
102. Dickinson, R. P.; Dack, K. N.; Steele, J. Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl) amino]alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists, Bioorg. Med. Chem. Lett., 1995, 5, 3017-3022.
103. Misra, R. N. Cardiovascular & Renal, Numerous approaches to reducing platelet aggregation. Exp. Opin. Invest. Drugs, 1995, 4, 1027-1031.
104. Gresele, P.; Arnout, J.; Deckmyn, H.; Huybrechts, E.; Pieters, G.; Vermylen, J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J. Clin. Invest., 1987, 80, 1435-1445. (Pubitemid 18027788)
105. 2 Receptor Antagonists and Synthetase Inhibitors. J. Med. Chem., 1994, 37, 26-39. (Pubitemid 24058810)